After several months of worsening infection trends in the context of a second wave of COVID-19, the figures appear to be stabilizing, reflecting the successful vaccination campaign and trends toward reduced mobility.  The 7-day moving average of new daily cases had recently risen to historic highs in recent weeks, exceeding 7,300. This week, that figure has fallen by 10% to approximately 6,700 as a result of the decline in new daily cases, and should continue its downward trend given the high vaccination rate. 

On a similar note, the 7-day moving average of positive tests out of the total number of tests has risen steadily over recent months, reaching 12% last week. This figure has begun to trend downward in recent days and currently stands at 11%. The worsening infection trends observed during the second wave had led to increases in the ICU bed occupancy rate, which rose to a record 96% just over a week ago.. We expect this number to decline in the coming weeks, assuming that the number of new daily cases continues to decline.

Chile has already vaccinated almost 8 million people, equivalent to 40% of the population. Similarly, a total of more than 5.5 million people have received both doses, meaning that 29% of the country has been fully vaccinated.

Chile continues to receive vaccine shipments at a rapid pace, with the latest shipment containing 266,175 doses from Pfizer. To date, the country has received 15,826,101 doses, the vast majority of which are from Sinovac. In fact, 90.1% of those vaccinated have received the Sinovac vaccine, with the rest receiving the Pfizer vaccine. 

This week, the Ministry of Health released the results of the Sinovac vaccine efficacy study. According to these results, the vaccine protects against symptomatic COVID-19 infection, as well as the most severe forms of the disease. The vaccine is 67% effective in preventing COVID-19 symptoms, 85% effective in preventing hospitalization, 89% effective in preventing ICU admission, and 80% effective in preventing death.